Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 1797 • 2013 ACR/ARHP Annual Meeting
A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis
Monica Luchi, Rosanne Fidelus-Gort, Diane Douglas, Haifeng Zhang, Robert Flores, Robert Newton, Peggy Scherle, Swamy Yeleswaram, Xuejun Chen and Victor Sandor, Incyte Corporation, Wilmington, DE
Background/Purpose: To characterize the safety and efficacy of INCB039110, a novel and selective JAK1 inhibitor, in patients with active RA. Methods: This phase 2, multicenter…
Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
P.H.P. de Jong¹, A.E.a.M. Weel², J.J. Luime³, P.J. Barendregt², A.H. Gerards⁴, P.A. van der Lubbe⁴, M.H. de Jager⁵, P.B. de Sonnaville⁶, D. van Zeben⁷, B.A. Grillet⁸ and J.M.W. Hazes³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁶Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁷Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁸Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…
Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Gabriela Ávila¹, Sara Marsal¹, Arnald Alonso¹, Carolina Diaz², Estefanía Quesada-Masachs², María López-Lasanta¹ and Isabel Acosta³, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, ³Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
Abstract Number: 1484 • 2013 ACR/ARHP Annual Meeting
Treatment With The Glucagon-Like Peptide-1 Analogue Liraglutide Is Associated With Amelioration Of Disease Activity In a Prospective Cohort Study Of Patients With Inflammatory Arthritis
Catherine Sullivan¹, Gadintshware Gaoatswe², James Gibney³, Marie Louise Healy⁴, Michele Doran⁵, David Kane¹, Donal O'Shea² and Ronan Mullan¹, ¹Department of Rheumatology, Tallaght Hospital, TCD, Dublin 24, Ireland, ²Obesity Immunology Group, Education and Research Centre, St Vincent's University Hospital, UCD, Dublin 4, Ireland, ³Department of Endocrinology, Tallaght Hospital, TCD, Dublin 24, Ireland, ⁴Department of Endocrinology, St James Hospital, TCD, Dublin 8, Ireland, ⁵Rheumatology Dept, St James's Hospital, Dublin, Ireland
Background/Purpose: Glucagon-like peptide-1 (GLP-1) analogues such as liraglutide, which are used for the treatment of type 2 diabetes (T2DM), mimic the action of endogenous incretin…
Abstract Number: 1460 • 2013 ACR/ARHP Annual Meeting
10 Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes
I.M. Markusse¹, G. Akdemir¹, M. van den Broek¹, L. Dirven¹, R.J. Goekoop², K.H. Han³, M. van Oosterhout⁴, P.J.S.M. Kerstens⁵, W.F. Lems⁶, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Haga Hospital, The Hague, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Long term studies with treat-to-target therapy are essential to guide treatment strategies. We report on a study that compared clinical and radiological outcomes of…
Abstract Number: 1475 • 2013 ACR/ARHP Annual Meeting
Subcutaneous Delivery Of Methotrexate Is Associated With Improved Treatment Survival Compared To Oral Administration For The Initial Treatment Of Patients With Early Rheumatoid Arthritis
Glen S. Hazlewood¹, J. Carter Thorne², Janet E. Pope³, Juan Xiong⁴, Gilles Boire⁵, Boulos Haraoui⁶, Carol A. Hitchon⁷, Edward C. Keystone⁸, Diane Tin⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³St Joseph Health Care, London, ON, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁷Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁸Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: To determine the comparative survival of initial treatment with subcutaneous (sc) methotrexate (MTX) versus oral MTX for patients with early rheumatoid arthritis (ERA) in…
Abstract Number: 1446 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate
T.W.J. Huizinga¹, Fiona Brock², Urs Kerkmann³ and Gaia Gallo³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Quanticate, Hitchin, Hertfordshire, United Kingdom, ³Pfizer Europe, Rome, Italy
Background/Purpose: Anti-TNF therapy in combination with a synthetic DMARD such as methotrexate (MTX) has been extensively shown to be superior to MTX and anti-TNF therapy…
Abstract Number: 1456 • 2013 ACR/ARHP Annual Meeting
Golimumab Levels, Anti-Drug Antibodies and Clinical Response In Rheumatoid Arthritis Patients At 28 Week Of Follow-Up
Eva L. Kneepkens¹, Dora pascual-Salcedo², Chamaida Plasencia³, Charlotte L. M. Krieckaert⁴, Desiree van der Kleij⁵, Michael T. Nurmohamed^4,6, Maria Teresa lópez-Casla⁷, Theo Rispens⁸ and Gertjan Wolbink^4,8, ¹Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Immunology unit, La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Immunology, La Paz University Hospital, Madrid, Spain, ⁸Sanquin Research, Amsterdam, Netherlands
Background/Purpose: Low drug levels of anti-Tumor Necrosis Factor (TNF) therapies are related to poorer response in patients with rheumatoid arthritis (RA). Furthermore, anti-drug antibodies (ADA)…
Abstract Number: 1285 • 2013 ACR/ARHP Annual Meeting
Choline Kinase: A Novel Target For Rheumatoid Arthritis
Monica Guma¹, Elsa Sanchez-Lopez², Alessia Lodi³, Stefano Tiziani⁴, Juan Carlos Lacal⁵, Michael Karin⁶ and Gary S. Firestein⁷, ¹Rheumatology, UCSD School of Medicine, La Jolla, CA, ²Pharmacology, UCSD School of Medicine, La Jolla, CA, ³nutritional Sciences, University of Texas at Austin, Austin, TX, ⁴Nutritional Sciences, University of Texas at Austin, Austin, TX, ⁵Oncology, University Hospital Fundacion Jimenez Diaz, Madrid, Spain, ⁶Departments of Pharmacology, UCSD School of Medicine, La Jolla, CA, ⁷Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Choline kinase (ChoKa) is an essential enzyme for phosphatidylcholine biosynthesis and is required for cell proliferation. The enzyme has also been implicated in cancer…
Abstract Number: 1057 • 2013 ACR/ARHP Annual Meeting
Regional Variations In Rheumatoid Arthritis Treatment and Health Outcomes Across The United States
Susan C. Bolge¹, Roxanne Meyer² and Kathy Annunziata³, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Scientific Affairs, LLC, Horsham, NY, ³Kantar Health, Princeton, NJ
Background/Purpose: Current ACR guidelines call for treatment of rheumatoid arthritis (RA) with non-biologic or biologic disease modifying anti-rheumatic drugs (DMARDs). The National Quality Forum has…
Abstract Number: 800 • 2013 ACR/ARHP Annual Meeting
A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment
Christopher R. Holroyd^1,2, Brian Davidson³, Sarah Bennett³, David Waghorn³, Caron Underhil³, Cyrus Cooper², Antonia Calogeras³, Elaine M. Dennison⁴, Nicholas C. Harvey⁵, Ray Armstrong³, Stephan Gadola⁶ and Christopher J. Edwards^7,8, ¹Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ²MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ³University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁵University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁶University of Southampton, Southampton, United Kingdom, ⁷NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁸University of Southampton, Southampton, United Kingdom
Background/Purpose: Reducing the dose of biological therapy may be possible for patients with rheumatoid arthritis (RA) who have achieved remission or low disease activity (LDA). …
Abstract Number: 497 • 2012 ACR/ARHP Annual Meeting
Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Hayssam Khalil¹ and Amir Tahami², ¹Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ²Janssen Canada Inc., Toronto, ON, Canada
Background/Purpose: Golimumab is a monthly self-injected anti-tumor necrosis factor alpha therapy for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). It…
Abstract Number: 499 • 2012 ACR/ARHP Annual Meeting
What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
Varun Dhir¹, Mandeep Singla², Palvi Goyal², Vinay Sagar², Aman Sharma¹ and Shefali K. Sharma², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Internal Medicine (Rheumatology Unit), Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Recent recommendations have suggested higher starting doses of methotrexate, i.e. 15 mg/week (3E initiative) in rheumatoid arthritis. However, studies comparing conventional (7.5mg) and newer…
Abstract Number: 372 • 2012 ACR/ARHP Annual Meeting
TRAF1/C5 Locus Is Associated with Response to Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatoid Arthritis
Helena Canhao¹, Ana M. Rodrigues², Maria José Santos³, Diana Carmona-Fernandes⁴, Bruno Bettencourt⁵, Jing Cui⁶, Fabiana Rocha⁵, Jose canas Silva³, Joaquim Polido Pereira⁷, Jose Alberto Pereira Silva⁸, José Antonio Costa⁹, Domingos Araujo¹⁰, Candida Silva¹¹, Helena Santos¹², Catia Duarte¹³, Fernando Pimentel-Santos¹⁴, Jaime C. Branco¹⁴, Robert M. Plenge¹⁵, Daniel H. Solomon¹⁶, Jacome Bruges Armas⁵, José A. P. Da Silva¹⁷, João E. Fonseca¹⁸ and Elizabeth W. Karlson¹⁹, ¹Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ²2- Rheumatology Research Unit,, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Lisbon, Portugal, ³Rheumatology Department, Hospital Garcia de Orta, E.P.E., Almada, Portugal, ⁴Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ⁵Seebmo, Hospital de Santo Espirito da Ilha Terceira, Ilha Terceira, Portugal, ⁶Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology Research Unit, Instituto Medicina Molecular, Lisbon, Portugal, ⁸Rheumatology Department, Santa Maria Hospital, Lisbon, Portugal, ⁹Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ¹⁰Rheumatology Department, Unidade Local de Saude, Ponte de Lima, Portugal, ¹¹Reumatology, Instituto Portugues Reumatologia, Lisbon, Portugal, ¹²Rheumatology, Instituto Português de Reumatologia, Lisboa, Portugal, ¹³Rheumatology, Hospitais da Universidade de Coimbra, Coimbra, Portugal, ¹⁴Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, ¹⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹⁶Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ¹⁷Serviço de Reumatologia, Centro Hospitalar e Universitário de Coimbra – Hospitais da Universidade de Coimbra, E.P.E., Coimbra, Portugal, ¹⁸Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, ¹⁹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Some of the allelic variants associated with rheumatoid arthritis (RA) susceptibility are related to tumor necrosis factor (TNF) signaling pathways. We hypothesized that they…
Abstract Number: 2638 • 2012 ACR/ARHP Annual Meeting
Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, 2004-2011
Ozgur Tunceli¹, Jeffrey R. Curtis², Tatia C. Woodward³, Siting Zhou¹, Yen-Wen Chen⁴ and Ancilla W. Fernandes³, ¹HealthCore, Inc., Wilmington, DE, ²Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ³MedImmune, LLC, Gaithersburg, MD, ⁴HealthCore, Inc, Wilmington, DE
Background/Purpose: While studies have assessed the efficacy of switching among biologic disease-modifying antirheumatic drugs (bDMARD), there is a lack of knowledge regarding the patterns of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].